The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer
Authors:
- Eric N.P. SubongESEric N.P. Subong
- Kerrie A. JonesKJKerrie A. Jones
- Penny L.S. MarschkePMPenny L.S. Marschke
- Jonathan I. EpsteinJEJonathan I. Epstein
- Daniel W. ChanDCDaniel W. Chan
- H. Ballentine CarterHCH. Ballentine Carter
- Albert A. LudererALAlbert A. Luderer
- Alan W. PartinAPAlan W. Partin
Open Access
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate CancerJournal of Urology, 1995
- Evaluation of Percentage of Free Serum Prostate-Specific Antigen to Improve Specificity of Prostate Cancer ScreeningJAMA, 1995
- Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigenUrology, 1995
- Diagnosis of Prostatic Carcinoma: The Yield of Serum Prostate Specific Antigen, Digital Rectal Examination and Transrectal UltrasonographyJournal of Urology, 1994
- SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMYUrologic Clinics of North America, 1993
- The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate CancerJournal of Urology, 1993
- Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign HyperplasiaJournal of Urology, 1990